Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer.
Tarantino P, Kim SE, Hughes ME, Kusmick RJ, Smith K, Brasó-Maristany F, Nyein Chan NN, Paré Brunet L, Alder L, Garcia-Cortes D, Gomez Tejeda Zanudo J, Pereslete AM, Noteware L, Moore H, Van Swearingen AED, Li T, Gupta H, D'Amico O, Martini A, Morganti S, Spindel J, Cook C, McLaughlin C, Dvir K, Garrido-Castro AC, Sammons S, Files J, Sendrick K, Buck S, Dillon D, Jeselsohn R, Li YY, Cherniack AD, LoRusso P, Lustberg M, Vega-León R, Pardo F, Davis J, Mueller C, Corgiat B, Curigliano G, Anders CK, Petricoin EF, Rimm DL, Prat A, Tayob N, Lin NU, Tolaney SM.
Tarantino P, et al. Among authors: cook c.
NPJ Precis Oncol. 2026 Mar 13. doi: 10.1038/s41698-026-01365-6. Online ahead of print.
NPJ Precis Oncol. 2026.
PMID: 41826432
Free article.